Posidorm

Melatonin, a natural hormone secreted by the pineal gland, is the regulator of normal sleep and its deficiency or imbalance is potentially a cause of many sleeping disorders.

POSIDORM^® (melatonin 1.5mg) is in the process of being developed for sleeping disorders in adults. POSIDORM's surge sustained formulation provides 0.5mg of melatonin as an immediate release to promote sleep and 1.0mg as sustained release over several hours to maintain sleep. This profile has been confirmed in Phase I trials. POSIDORM has completed proof of principle studies.

Melatonin therapy is the obvious first line approach to many sleeping disorders and its utility has been established by a large and ever–growing bibliography. Melatonin’s pharmacology and mode of action means it may not have the limitations of many current hypnotic therapies. Further indications are envisaged post-launch including jetlag and sleeping disorders in the blind, shift workers and children with neurodisabilities.

Click here to contact Alliance business development to discuss licensing partnership opportunities with ISPRELOR or POSIDORM.